OrbiMed rings up $950M for its transatlantic biotech Fund VI

John Carroll

has come through with a whopping $ 950 million venture , committing anywhere from $ 10 million to a hefty $ 75 million to each of about 30 new companies.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS